Pharma Capital

Silence Therapeutics gains further patent protection for its innovative chemical modification technology in the US

Silence said that the allowed claims of both patents, when granted, will provide it with further protection for its innovative chemical modification technology in the US
Therapeutics testing
The group said it believes these allowed claims are relevant to third party medicines in ongoing clinical trials

Silence Therapeutics PLC (LON:SLN) has gained further protection for its US patent estate with the announcement that the US Patent and Trade Mark Office has issued a notice of allowance for its patent application 15/594,438, and with a further key US patent to be granted tomorrow.

The AIM-listed firm - a developer of novel RNA therapeutics for the treatment of serious diseases with unmet medical needs – said it has made the relevant payment of grant fees for US patent application 15/594,438 and normal practice is that the granted patent will now be issued by the US Patent and Trade Mark Office.

READ: Silence Therapeutics continuing to make strong progress on drug pipeline

It added that, as previously mentioned on 31 July 2017, the US Patent and Trade Mark Office issued a notice of allowance for US patent application 15/589,971, which it will issue tomorrow as US patent 9,758,784.

Silence said that the allowed claims of both patents, when granted, will provide it with further protection for its innovative chemical modification technology in the US.

The group said it believes these allowed claims are relevant to third party medicines in ongoing clinical trials.

In mid afternoon trading Silence shares were 4.3%, or 7p higher at 170p.

Further protection for Silence’s US patent estate

Ali Mortazavi, Silence’s chief executive officer, commented: "This notice of allowance and grant in the US provides further protection for our US patent estate.

“Combined with our other recently allowed US patent applications, we will have ten granted US patents, one US patent application, three granted European patents and four European patent applications encompassing our chemical modification technology.”

He added: “Our chemical modification patent portfolio also encompasses patents and patent applications in the following countries: Australia, Brazil, Canada, China, Israel, India, Japan, Korea, Mexico and South Africa.

The CEO concluded: “We continue to believe that several third party late-stage clinical RNAi candidates require licences under our patent portfolio and that such licences could have a material financial effect on Silence."

View full SLN profile

Silence Therapeutics plc Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.